Ages 13–24 · Consent · Privacy · PrEP · Care

HIV & young people — your health, your rules, your future.

Last reviewed:

Health information — Educational information, not medical advice. Talk with your healthcare provider about your care and treatment decisions.

About one in five new HIV diagnoses in the United States is a person between 13 and 24 — and young people have the lowest linkage-to-care rate of any age group. This is the practical guide: what you can consent to without a parent in all 50 states, how to keep an HIV visit off your family's insurance statement, PrEP under 18 under current FDA labels, where youth-specific HIV care lives, and what Florida law actually says.

Share this article Facebook X WhatsApp Text Email LinkedIn Reddit Threads Bluesky
← Home

If you are somewhere between 13 and 24 and you are reading this because you are worried about HIV — worried you were exposed, worried about a test result, worried about who might find out — the most important thing to know first is that you have more control over this than you have probably been told. Not total control. But real, specific, legally backed control over who gets tested, who gets treated, and in most cases who finds out.

That matters because young people carry a share of the U.S. HIV epidemic that is wildly out of proportion to how much attention they get. In 2024, there were 38,793 HIV diagnoses among people aged 13 and older in the United States and seven territories and freely associated states, and 6,872 of them — about one in five — were among people aged 13 to 24.1 Meanwhile, only about 6% of high school students have ever been tested for HIV.5 And roughly 44% of adolescents and young adults living with HIV do not yet know they have it.4

Those three facts together describe the actual problem. It is not that young people are careless. It is that the systems built to test and treat people were designed around adults with their own insurance, their own transportation, their own mailing address, and no one else opening their mail. This page is about the workarounds — the consent laws, the privacy rules, the clinics, the medications, and the crisis lines that exist specifically so that being young does not have to mean being stuck.

Quick answer: Minors have routes to confidential HIV/STI services, but the age, service, consent, and notification rules vary by state. Do not assume every minor can independently obtain every HIV service or PrEP. In Florida, §384.30 permits qualified providers to examine and treat minors for sexually transmissible diseases without parental consent and protects confidentiality, subject to statutory exceptions.78

A handful of states set a minimum age or let a provider notify a parent in some situations. Those details are below, state by state.

The numbers — who HIV is actually reaching

Start with what federal surveillance shows, because the pattern is specific and it is not random.

Of the 6,872 HIV diagnoses among people aged 13 to 24 in 2024, the counts by age band were 23 among 13- to 14-year-olds, 320 among 15- to 17-year-olds, 1,026 among 18- to 19-year-olds, 2,929 among 20- to 22-year-olds, and 2,574 among 23- to 24-year-olds.1 The curve climbs steeply in the late teens and peaks in the early twenties — which is exactly the window in which most people are also aging out of pediatric care, leaving home, changing insurance, and losing whatever adult was previously scheduling their appointments.

Race, geography, and gender

Among those 6,872 young people, 3,291 (about 48%) were Black or African American and 2,392 (about 35%) were Hispanic or Latino, compared with 797 who were white.1 Together, Black and Latino young people accounted for roughly five out of every six diagnoses in this age group. That is not a statement about behavior. It is a statement about which communities have been under-resourced for testing, prevention, and treatment access for four decades.

Geographically, 3,892 of the 6,872 — about 57% — were in the South.1 By comparison, the West accounted for 1,046, the Midwest 949, and the Northeast 936. The southern concentration tracks closely with lower rates of Medicaid expansion, thinner public transit, fewer youth-serving HIV clinics, and school health curricula that often do not mention HIV prevention at all.

By sex, 6,015 of the diagnoses were among males and 857 among females.1 Among young men, the overwhelming majority of diagnoses were attributed to male-to-male sexual contact. Among young women, most were attributed to heterosexual contact, with 78 attributed to injection drug use.1

Different CDC products answer different questions. HIV diagnosis surveillance includes gender-identity data; national incidence estimates do not provide separate transgender and additional-gender estimates because the numbers are too small for reliable estimation. A sex-assigned-at-birth table does not describe every young person’s identity or needs. See CDC’s explanation of the estimation limit.1

Young people already living with HIV

At the end of 2024, 27,406 people aged 13 to 24 were living with diagnosed HIV in the United States and seven territories and freely associated states — 22,343 male and 5,063 female.1 Of those, 3,341 acquired HIV perinatally, meaning around the time of birth.1 That last group deserves specific mention: several thousand young Americans have been living with HIV literally their whole lives, have been taking medication since before they could read, and are now navigating adulthood, dating, and disclosure with a diagnosis they never got to react to as news.

The good news, and the gap

Estimated new HIV infections among people aged 13 to 24 fell by about 30% between 2018 and 2022.3 That is one of the sharpest declines in any age group, and it is real progress driven by testing, treatment as prevention, and PrEP.

The gap is on the care side. In 2024, 83.1% of people newly diagnosed nationally were linked to HIV care within one month — but among people aged 13 to 24, linkage was 82.0%, the lowest of any age group.2 At the same time, young people aged 13 to 24 had the highest proportion of diagnoses at stage 0, at 11.2% — meaning very recent infection caught early, often through repeat testing.2 And about 34% of adolescents and young adults with diagnosed HIV are not virally suppressed.4

Read those together and the story is clear: young people are getting diagnosed earlier than anyone, and then falling through the floor on the way to treatment. The rest of this page is about the specific reasons that happens, and what actually fixes them.

This is the single most misunderstood thing in youth HIV care, including by some clinic staff.

States have laws allowing at least some minors to consent to STI services. HIV testing, ongoing HIV treatment, and prevention are not necessarily governed identically; age limits, notification provisions, and other laws can affect access. Ask a clinic familiar with current local law about the service you need.7

The eight states with age floors

Eight states set a minimum age rather than allowing any minor to consent. Alabama, California, Delaware, and Illinois set the floor at 12; New Jersey sets it at 13 specifically for HIV; and Hawaii, Idaho, and North Dakota set it at 14.7 Idaho is a genuine tangle: a 2024 provision of Idaho Code (§ 32-1015) requires parental consent for health care provided to minors, and there is not yet case law resolving how that interacts with the state's existing law letting 14-year-olds consent to STI services.7 If you are a young person in Idaho, ask the clinic directly how they are handling it before you give your name.

The sixteen states where a provider may tell your parents

Consenting on your own and staying private are two different questions. Sixteen states have parental notification provisions attached to minors' STI services: Alabama, Arkansas, Delaware, Georgia, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Missouri, Montana, New Jersey, and Oregon.7 In most of these, notification is permitted rather than required — the provider may tell a parent, and many choose not to.

Three states are more specific. In Iowa, a provider is required to inform a minor's legal guardians of a positive HIV test result. In Massachusetts, notification is required if the minor's life or limb is endangered. In New Jersey, a provider must notify a parent if the minor has experienced sexual assault, unless doing so is not in the minor's best interest.7

Florida is not on that list. In Florida, a minor may consent, and the state has no parental notification provisions for STI services.7

Florida Statute 384.30, in plain language

Florida's law is unusually clear, and worth knowing by name. Section 384.30 says the Department of Health, licensed physicians, licensed nurses, and any public or private hospital, clinic, or health facility "may examine and provide treatment for sexually transmissible diseases to any minor," and that "the consent of the parents or guardians of a minor is not a prerequisite for an examination or treatment."8

Subsection (2) is the part almost nobody knows about, and it is the strongest privacy language in this whole article: the fact of consultation, examination, and treatment of a minor for a sexually transmissible disease is confidential, exempt from public records disclosure, and "shall not be divulged in any direct or indirect manner, such as sending a bill for services rendered to a parent or guardian."8

Read that again. Florida law names the billing statement specifically as a prohibited form of disclosure. If you are a minor in Florida and a clinic tells you a bill has to go to your parents, they are describing their billing software, not the law.

What about PrEP, not just testing?

PrEP consent can differ from consent to HIV testing or STI treatment. CDC’s 2020 review describes the legal landscape at that time; its state counts are not a current legal determination. Ask a local adolescent-health or sexual-health clinic to explain current consent and confidentiality rules before arranging services.10

Allowing minors to autonomously consent to PrEP does not mean that access to the health care service will remain confidential. — Mary R. Tanner, MD, and colleagues, CDC, MMWR Recommendations and Reports, 2020, on the gap between consent law and actual privacy.10

CDC's current clinical guidance tells providers to consult local law, to explicitly discuss confidentiality with adolescent patients up front, and — in its own words — that if the law permits, providers should allow adolescent patients who would benefit from PrEP to decide for themselves whether to take it.11

Confidentiality is a right, not a favor. If a clinic is not respecting it, you can find one that does. You are allowed to call ahead and ask, before you give your name: "Do you see minors without parental consent? Does anything get mailed home? Can I get my results by text or through a portal?" A clinic that cannot answer those three questions clearly is telling you something useful.

The Explanation of Benefits problem

Here is the failure mode that undoes more young people's privacy than any consent law: the envelope.

If you are covered as a dependent on a parent's health insurance, the plan generates an Explanation of Benefits — an EOB — after a claim. It is not a bill, but it lists the date, the provider, and often a code or plain-English description of the service. It goes to the policyholder. CDC named this problem directly: billing documentation from commercial health insurance companies in an Explanation of Benefits "provides a potential mechanism of disclosure of services provided to adolescents covered under their parents' or guardians' health insurance."10

Even when you may consent to care independently, an insurance claim can disclose a visit through an EOB, portal, or other communication. Discuss the clinic’s and plan’s privacy procedures before a claim is submitted.

The federal tool: a confidential communications request

HIPAA includes a specific, enforceable right most people have never heard of. Under 45 CFR § 164.522(b), a covered health care provider "must permit individuals to request and must accommodate reasonable requests" to receive communications of protected health information "by alternative means or at alternative locations."9 A provider may not require you to explain why you are asking.9

Health plans have a slightly different standard: a plan must accommodate reasonable requests to send communications by alternative means or to an alternative location "if the individual clearly states that the disclosure of all or part of that information could endanger the individual."9 The plan may require the request in writing, may require that endangerment statement, may ask you to specify the alternative address or contact method, and may ask how payment will be handled.9

In practice that means the request needs three things: a specific alternative address, phone number, or email; a clear statement that disclosure at the usual address could endanger you; and it should be in writing. Call the member services number on the insurance card and ask for the "confidential communications request" form.

The same regulation contains a second lever. Providers must permit you to request restrictions on uses and disclosures for treatment, payment, and health care operations, and there is a specific provision covering restriction of disclosure to a health plan where the service has been paid for in full out of pocket.9 Translated: if you pay cash for a visit, you can ask that it never be sent to the insurance company at all — which means no claim, and therefore no EOB.

Five ways to keep an HIV visit off the kitchen table:

1. Ask about confidential, no-claim options. Some public-health or community services offer free testing. Ryan White care has eligibility and payer-of-last-resort rules; it cannot be assumed to bypass available insurance. Ask the clinic how it will handle billing before the visit.16

2. File a confidential communications request with the plan. In writing, with an alternative address and a statement that disclosure could endanger you.9

3. Ask the provider to redirect all mail and calls to you. Providers must accommodate reasonable requests and cannot make you justify it.9

4. Pay out of pocket and ask for a disclosure restriction. No claim, no paper trail through the plan.9

5. In Florida, cite the statute. Section 384.30(2) prohibits divulging a minor's STI care "in any direct or indirect manner, such as sending a bill for services rendered to a parent or guardian."8 Ask the billing office to note it in your chart.

One more practical note: insurance disruption is not just a privacy problem, it is an adherence problem. In a study of young men who have sex with men aged 16 to 29, the most commonly reported reasons for stopping PrEP included difficulty getting to appointments, a lapse in insurance coverage, and a sense of no longer needing it.10 If your coverage is about to change, raise it with your clinic before it happens, not after.

Getting tested — the confidential routes

CDC recommends that everyone between 13 and 64 be tested for HIV at least once, and that people with ongoing risk factors test at least annually.22 Given that only about 6% of high school students report ever having been tested — and that reported condom use among high school students fell from 60% in 2011 to 52% in 2021 — that once-in-a-lifetime baseline is not being met.5

You have more options than a doctor's office.

Free HIV self-tests mailed to you

Together TakeMeHome offers free mailed HIV self-tests to eligible people aged 17 or older in the United States, including Puerto Rico. The national program is at together.takemehome.org; related TakeMeHome programs have local eligibility rules. FDA permits the OraQuick oral self-test from age 14, but the national mail program’s minimum age remains 17. Younger teens can ask a local clinic about confidential testing.[23]17

An oral-swab self-test gives you a result at home in about 20 minutes, with no clinic, no insurance claim, and no one else in the room. That is often the single most useful first step for a young person who is not sure who they can trust yet.

The limits of self-tests, honestly

Two caveats matter. First, self-tests are less sensitive than laboratory tests at detecting very recent infection, and for that reason CDC says HIV self-tests are usually not recommended for people who are taking PrEP, though clinicians may consider them when other options are not available.17 Second, a reactive self-test result is a signal to get confirmatory laboratory testing, not a final answer.

Some services offer home collection with specimens mailed to a lab. The type of specimen and test determine the window period; home collection does not automatically detect a very recent infection. Tell a clinician about recent exposure, symptoms, and PrEP or PEP use so the right HIV tests and follow-up can be arranged.17

In-person options that tend to be youth-friendly

If you are in Florida, the state HIV/AIDS Hotline is 1-800-352-2437 in English, 1-800-545-7432 in Spanish, and 1-800-243-7101 in Haitian Creole, with 1-888-503-7118 for hearing and speech impaired callers; you can also text FLHIV to 898211.22

PrEP when you are under 18

PrEP — pre-exposure prophylaxis — is HIV medication taken by someone who does not have HIV, to prevent acquiring it. There are now four FDA-approved PrEP medications in the United States, and the age and weight rules on them have changed enough recently that a lot of well-meaning clinicians are working from outdated information.

The four options and who they are labeled for

CDC lists emtricitabine/tenofovir disoproxil fumarate (F/TDF, brand name Truvada or a generic), emtricitabine/tenofovir alafenamide (F/TAF, brand name Descovy), and cabotegravir extended-release injectable suspension (CAB, brand name Apretude), and states that these medications are approved to prevent HIV in adults and adolescents weighing at least 77 pounds (35 kilograms).11 Daily oral F/TDF is recommended for anyone with sexual or injection risk factors; daily oral F/TAF is recommended for sexual transmission but excludes people likely to acquire HIV through receptive vaginal sex, because it has not been studied in that population.11

Apretude's FDA prescribing information states it is indicated for PrEP in adults and adolescents weighing at least 35 kg. It is given as an injection, with a second dose one month later and then every two months.11 The adolescent indication is supported by open-label trials — HPTN 083-01 and HPTN 084-01 — that enrolled 64 adolescents aged 12 to under 18 weighing at least 35 kg; 62 received at least one injection, the safety profile was comparable to adults, and no HIV infections occurred among them.12 Safety and effectiveness have not been established in children under 12.12

The newest option is lenacapavir (brand name Yeztugo), approved on June 18, 2025 and indicated for PrEP in adults and adolescents weighing at least 35 kg. After initiation dosing, it is given as a 927 mg subcutaneous injection every 26 weeks — twice a year.13 In September 2025, CDC issued a formal recommendation strongly recommending lenacapavir injections every six months as PrEP for people weighing at least 77 pounds (35 kg), citing efficacy of 100% among females and 96% in a primarily male study population over 52 weeks.14

A real discrepancy worth naming. CDC's clinician-facing PrEP guidance page, last updated April 30, 2026, still contains older language stating that cabotegravir "has not been studied in men or women <18 years of age" and that "until CAB is determined to be safe for this population and approved by the FDA, CAB injections are not recommended for adolescents <18 years old."11 The FDA prescribing information for Apretude, however, states the adolescent indication and describes the adolescent trials that supported it.12

If a provider tells you injectable PrEP is off the table because you are under 18, it is fair and useful to ask them to look at the current FDA label. You are not being difficult; you are being current.

Bones, and why it comes up

The most-studied safety question in adolescent PrEP is bone mineral density with tenofovir disoproxil fumarate. Data have shown bone density changes in young gay and bisexual men during PrEP use and after a 48-week trial period, and while declines reversed in adults, they persisted in younger men.11 Because F/TAF appears to have less bone effect than F/TDF, CDC suggests considering F/TAF for adolescent male patients starting PrEP.11

The underlying trials are worth knowing by name, because they are the reason adolescent PrEP exists at all. ATN 113 was an open-label study in U.S. adolescents aged 15 to 17; ATN 110 covered ages 18 to 22; and ATN 117 examined vitamin D status and tenofovir exposure in relation to bone toxicity.10 Overall, the available data support the safety of PrEP in adolescents, and routine DXA bone scans are not recommended for people taking PrEP.10

The part nobody says out loud: taking it is the hard part

The ATN studies found something that has shaped adolescent PrEP care ever since. Adherence declined when clinic visits moved from monthly to quarterly — in both the younger ATN 113 participants and the older ATN 110 participants — even though participants received structured, client-centered adherence counseling.10 CDC's guidance draws the obvious conclusion: adolescents prescribed PrEP may benefit from more frequent, supportive interactions.11

Practical translation: if you are starting PrEP, ask for monthly check-ins rather than quarterly, even if the clinic offers quarterly by default. Ask about text reminders, peer navigators, flexible or after-hours appointments, and whether they can do refills without a full visit.10 None of that is asking for special treatment; it is the evidence-based version of the service.

Two other notes. On-demand "2-1-1" dosing exists for some people who have sex infrequently, but CDC specifically says it should not be prescribed to people who might have trouble with a complex dosing schedule, and names adolescents as an example.11 And if your clinician wants prescribing advice, the National Clinician Consultation Center PrEPline is at 844-275-6222, Monday through Friday.11[26]

A positive result at 16 — what happens next

First, the medical sequence, so nothing is a surprise. A reactive rapid or self-test is followed by confirmatory laboratory testing. Then baseline bloodwork — viral load, CD4 count, and a resistance test — plus screening for other infections. Then antiretroviral therapy, ideally started fast, sometimes the same day.

Most people can get HIV under control within about six months of starting treatment.6 That is the whole arc. Not decades. Months.

You can take time to decide whom to tell in your personal life. Ask your clinician about confidentiality, any legally required reporting or partner-notification rules, and a safe disclosure plan. The immediate priority is confirming the diagnosis, linking to care, and starting appropriate treatment.

Among 2024 U.S. diagnoses, ages 13–24 had the highest proportion classified at stage 0 (11.2%), indicating very early detection, and the lowest age-group linkage to care within one month (82.0%). These population measures do not predict an individual’s outcome. Arrange care and ART promptly; a delay is a reason to seek help, not a reason to give up.2

Research networks built specifically for you

The Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) is the only multicenter research network in the United States devoted to the health and well-being of adolescents and young adults living with or at risk for HIV, focused specifically on ages 13 through 24.15 It was started in 2001 by the NICHD Maternal and Pediatric Infectious Disease Branch and is co-funded by the National Institute on Drug Abuse and the National Institute of Mental Health.15

ATN's stated priorities read like a list of exactly the gaps described on this page: undiagnosed HIV among youth, persistent new acquisitions, care engagement, antiretroviral adherence and viral suppression, and adverse outcomes.15 The current cycle launched in 2023 and is organized around a Scientific Leadership Center and an Operations and Collaborations Center; specific current sites are not listed publicly on the network's overview page, so the practical move is to ask your HIV clinic whether they participate in or refer to ATN studies.15 Being in a study is not a last resort — for young people it often means more frequent contact, more support, and more people whose job is to keep you in care.

Where youth-specific HIV care lives

The Ryan White HIV/AIDS Program is the reason most people in the U.S. can get HIV care regardless of income, and it has a part written specifically for young people.

The program has five parts. Part A funds Eligible Metropolitan Areas and Transitional Grant Areas. Part B funds states and territories, including the AIDS Drug Assistance Program. Part C funds community-based outpatient ambulatory care. Part F funds AIDS Education and Training Centers, Special Projects of National Significance, dental programs, and the Minority AIDS Initiative.16

Part D is the one to ask for by name. It provides grants to local community-based organizations and funds medical care for low-income women, infants, children, and youth living with HIV, plus support services for them and their family members.16 That family-inclusive design is the point: a Part D program is built on the assumption that a young person's care involves transportation, food, housing instability, guardianship questions, and siblings — not just a prescription.

What youth-friendly care actually looks like

When you are calling clinics, these are the things worth asking about, because they are the things that predict whether you stay in care:

If a clinic answers yes to most of that, take the appointment even if it is farther away. Continuity beats convenience.

School, college, and who has to know

Almost nobody. That is the short version.

Your HIV status is health information. Schools, universities, roommates, teammates, coaches, and professors have no automatic entitlement to it. There is no academic form that requires it, no dorm policy that requires it, and no sport that requires it. Disclosure to a roommate is never required — it is a choice you make when and if you decide the relationship warrants it.

What matters practically at school is logistics and privacy plumbing:

Medication logistics

Antiretroviral therapy is once-daily for most people, which is far easier to manage in a dorm than in a household with a locked medicine cabinet and a curious sibling. Think about a 90-day mail-order supply shipped to a campus address, a pill organizer that does not announce itself, a phone alarm rather than a labeled bottle on a desk, and a plan for breaks and travel. If you are also on a parent's insurance, the mail-order pharmacy address is one more thing a confidential communications request can redirect.9

Campus health and student insurance

College health centers can usually prescribe and manage PrEP and often HIV care, or refer you. The catch is the same one from earlier: if you are billing a parent's plan, the EOB goes to the policyholder, and CDC has flagged that mechanism explicitly.10 A student health plan in your own name, a confidential communications request, or a Ryan White–funded clinic off campus each solve it in a different way.916

If you are transferring care to a college town

Do this before the semester starts, not after you run out of medication. Get a copy of your labs, the name of your regimen, your case manager's contact, and a written referral. Ask your current clinic to make the introduction directly — a warm handoff from one clinician to another is the single most reliable way to avoid a gap, and gaps are where viral rebound happens.

Transitioning to adult HIV care

If you grew up in pediatric or adolescent HIV care, the transition to adult care is the point where the system most often loses people. The reasons are structural, and they stack.

Moving to adult care can involve new staff, insurance changes, and different appointment routines. Plan the transition with both teams. PrEP studies in adolescents found adherence declined after visits became less frequent, but those results do not establish an exact ART transition schedule for every young person.10

Layer that on top of the fact that 13- to 24-year-olds already have the lowest linkage-to-care rate of any age group,2 and about a third of adolescents and young adults with diagnosed HIV are not virally suppressed,4 and transition looks less like a milestone and more like a cliff.

A transition checklist that actually holds

Mental health, crisis support, and substance use

A new HIV diagnosis in your teens or early twenties arrives on top of everything else that age already involves. Anxiety, depression, isolation, and fear of disclosure are ordinary responses, not weakness, and they are also the strongest practical predictors of whether someone stays in care and takes medication consistently.

If you need someone right now

The 988 Suicide & Crisis Lifeline is reachable by calling or texting 988 from anywhere in the United States.19

For LGBTQ+ young people specifically, The Trevor Project provides crisis counseling by text, chat, or phone, 24 hours a day, 365 days a year, from anywhere in the U.S. It states plainly that the service is confidential and 100% free, that counselors are trained in the challenges LGBTQ+ young people face, and that you can share as much or as little as you want.18 It is also honest about limits: in very specific instances of abuse or a clear concern of an in-progress or imminent suicide, counselors may need to contact a child welfare agency or emergency service.18 Knowing that boundary in advance is better than discovering it mid-conversation.

Substance use, without the lecture

Substance use and HIV intersect in young people's lives constantly, and the useful response is practical rather than moral. CDC's clinical guidance directs providers to link patients to syringe services programs where they are legal and available, to prescribe syringes, and to advise patients that syringes can be purchased at pharmacies without a prescription where local law allows.11 Federal guidance also directs providers to screen for barriers such as unstable housing and to offer resources, referrals, or counseling.10

Nothing you say about substance use should cost you your HIV care. If it does, that is a signal about the clinic, not about you — and adolescent-focused and Ryan White programs are generally the most practiced at having that conversation without flinching.16

Ask for integrated care

When you are choosing a clinic, ask whether behavioral health is in the same building and on the same chart. Co-located care means one trip, one intake, one set of people who already know your situation — which for a young person without a car is often the difference between getting therapy and not.

Sex, dating, and disclosure — the version that is actually true

Here is the fact that changes the entire emotional weight of an HIV diagnosis, and that a lot of young people are never told directly: if you have an undetectable viral load, you will not transmit HIV through sex. That is CDC's own language, and it is what "Undetectable = Untransmittable" — U=U — means.6

Most people can achieve viral suppression within six months of starting effective treatment. Maintaining a viral load below 200 copies/mL prevents sexual transmission. Pregnancy, birth, and breastfeeding have separate prevention guidance: ART and infant care greatly reduce transmission, but the U=U zero-risk statement does not extend to those routes. Use sterile equipment for every injection.[24]6

So the honest framing for a 19-year-old is not "you have to be careful forever." It is: take your medication, get to undetectable, stay there, and sex is not a transmission risk. That is a reasonable thing to build a life and a relationship on.

Disclosure to partners

Disclosure is a decision with legal, emotional, and safety dimensions that vary by state, and it is worth reading about in depth rather than improvising. A few things are broadly true: you get to choose the timing; you get to choose the setting; the first conversation does not have to be the whole conversation; and rehearsing it once out loud, with a counselor or a peer navigator, makes it go dramatically better. If a partner does not have HIV, they can also start PrEP — which turns a scary asymmetry into a shared, boring, manageable routine.11

Apps, photos, and practical safety

Dating apps are how a large share of young people meet partners, and the risks that actually materialize are usually not medical. They are location exposure, screenshots, and coercion. Practical habits: turn off precise-distance features; keep your face out of photos you would not want reposted; do not put your status, your school, or your workplace in a profile you would not want a relative to find; meet in public first; tell one friend where you are going. If someone threatens to out you, that is coercion — not a negotiation you have to participate in.

On nudes: assume anything sent can be saved. That is not a moral position, it is a technical one. And if you are under 18, sharing sexual images of a minor — including yourself — carries legal exposure that varies by state and is worth understanding before it becomes urgent.

Trans and nonbinary youth — HIV care in a shifting legal landscape

For trans young people, HIV and gender-affirming care may be provided together or by different teams. Coordination and trust matter either way. A clinic closure or funding restriction can disrupt appointments, referrals, and medication access, so ask for a continuity plan for each part of your care.

As of its August 14, 2026 update, KFF's tracker counts 27 states that have enacted laws or policies limiting youth access to gender-affirming care, with about half of transgender youth aged 13 to 17 living in a state that has enacted such a law. Twenty-five bans remain in place, with bans in Montana and Arkansas blocked by court order, and 24 states impose professional or legal penalties on health care practitioners who provide gender-affirming care to minors.20

On August 11, 2026, CMS announced a final rule restricting federal Medicaid and CHIP funding for certain gender-affirming medical treatments for young people, scheduled to take effect October 13, 2026. It includes a limited tapering period for some existing hormone treatment and does not remove mental-health coverage. State-only funding, state laws, and litigation may affect access; ask your care team about the current rules and a continuity plan.[25]21

Why this shows up in HIV outcomes

The mechanism is not complicated. When the clinic that provided hormones stops providing them — or closes, or the clinician leaves the state — the young person often stops going. HIV testing, PrEP refills, ART refills, and behavioral health were bundled into that same visit. Losing one service in a bundle tends to cost you the whole bundle.

Practical hedges, none of them ideal, all of them better than nothing:

Florida specifics

Florida is one of the most consequential states in the country for young people and HIV, in both directions — a heavy epidemic, and unusually protective minor-consent language.

The epidemic

In 2023, Florida recorded 4,725 new HIV diagnoses. Of those, 139 (about 3%) were among people aged 13 to 19 and 1,285 (27%) were among people aged 20 to 29 — meaning more than a quarter of the state's new diagnoses were in the twenties alone.22 At the end of 2023, 128,497 people with HIV were living in Florida, a rate of 566.4 per 100,000, with about one in 177 adults living with HIV statewide — and one in 64 Black Floridians.22

Florida ranked third among states for HIV diagnosis rate based on 2022 diagnoses, at 19.3 per 100,000 against a national rate of 11.3.22 The Miami–Fort Lauderdale–West Palm Beach metro had the highest HIV diagnosis rate of any U.S. metropolitan statistical area in 2022, at 30.8 per 100,000, with Orlando–Kissimmee–Sanford also in the top ten at 21.0.22 By county in 2023, Miami-Dade recorded 1,048 diagnoses, Broward 588, Orange 461, Hillsborough 378, Palm Beach 282, Duval 273, and Pinellas 164.22

Put next to the national finding that 57% of youth diagnoses are in the South,1 Florida is not a footnote in the youth HIV story. It is a main character.

The law, which is on your side

Guttmacher's July 2026 tracking lists Florida as a state where a minor may consent to STI services, with no parental notification provisions.7 Section 384.30, Florida Statutes, is the underlying law: parental consent "is not a prerequisite for an examination or treatment," and a minor's STI care is confidential and may not be divulged directly or indirectly, including by sending a bill to a parent or guardian.8

If you are a young person in Florida, that is a real, citable thing you can say at a front desk.

How to find care here

Start with the Florida HIV/AIDS Hotline: 1-800-352-2437 (English), 1-800-545-7432 (Spanish), 1-800-243-7101 (Haitian Creole), 1-888-503-7118 (hearing/speech impaired), or text FLHIV to 898211.22 Ask two specific questions: whether the program is Ryan White Part C or Part D funded, and whether it sees minors without parental consent. Part D programs are the ones funded specifically to serve youth and families.16 County health departments in Miami-Dade, Broward, Orange, Duval, Hillsborough, and Pinellas all sit in the highest-volume counties in the state and are the most likely to have youth-experienced staff on site.22

What to do this week

Some options are free and confidential, while others have age, consent, eligibility, or billing requirements. Pick a next step that fits your situation and ask the service about those details.

You have options for HIV testing, treatment, and prevention. Ask about current age and consent rules, insurance communications, and cost before a visit. If you have HIV, prompt effective treatment protects your health, and maintaining a viral load below 200 copies/mL prevents sexual transmission.717121396

References & Sources

Federal HIV surveillance and clinical guidance (CDC, NIH, HRSA, FDA), the Guttmacher Institute's minor-consent tracking, Florida statute and Florida Department of Health surveillance, the HIPAA Privacy Rule, and KFF policy tracking.

  1. CDC — HIV Diagnoses, Deaths, and Prevalence (National HIV Surveillance System). Centers for Disease Control and Prevention. National surveillance page and 2024 data release; the downloadable 2024 surveillance data tables provide diagnoses and prevalence among people aged 13–24 by age band, race and ethnicity, sex, transmission category, and region, including the 6,872 diagnoses of 38,793 total and the 27,406 people aged 13–24 living with diagnosed HIV at year-end 2024. ↩
  2. CDC — Monitoring Selected National HIV Prevention and Care Objectives (2026 release). Centers for Disease Control and Prevention. Care-continuum measures by age for 2024, including linkage to care within one month (83.1% overall; 82.0% among ages 13–24, the lowest of any age group) and stage 0 detection (11.2% among ages 13–24, the highest of any age group). ↩
  3. CDC — Estimated HIV Incidence and Prevalence in the United States. Centers for Disease Control and Prevention. Modeled incidence estimates, including the approximately 30% decline in estimated new HIV infections among people aged 13–24 from 2018 to 2022. ↩
  4. HIV and Adolescents and Young Adults. NIH HIVinfo (National Institutes of Health). Federal fact sheet on ages 13–24: roughly 44% of adolescents and young adults with HIV do not know they have it, and about 34% of those with diagnosed HIV are not virally suppressed. ↩
  5. CDC — HIV Testing and Youth (National Youth HIV & AIDS Awareness Day). Centers for Disease Control and Prevention. Youth testing and prevention behavior data, including that only about 6% of high school students have ever been tested for HIV and that condom use fell from 60% in 2011 to 52% in 2021. ↩
  6. CDC — Treating HIV. Centers for Disease Control and Prevention. Federal statement of Undetectable = Untransmittable ("If you have an undetectable viral load, you will not transmit HIV through sex"), reduction of perinatal transmission with appropriate care, and the observation that most people can get HIV under control within six months. ↩
  7. Minors' Access to STI Services. Guttmacher Institute (as of July 2026). State-by-state tracking: all 50 states and DC allow minors to consent to STI testing and treatment; eight states set minimum ages; 16 states have parental notification provisions; Iowa requires notification of a positive HIV test; Florida allows minor consent with no notification provisions. ↩
  8. Florida Statutes § 384.30 — Minors' consent to treatment. Florida Legislature. Parental consent "is not a prerequisite for an examination or treatment," and a minor's STI consultation, examination, and treatment is confidential and "shall not be divulged in any direct or indirect manner, such as sending a bill for services rendered to a parent or guardian." ↩
  9. 45 CFR § 164.522 — Rights to request privacy protection for protected health information. Legal Information Institute, Cornell Law School (HIPAA Privacy Rule text). Providers must accommodate reasonable requests for communications by alternative means or at alternative locations and may not require an explanation; health plans must accommodate reasonable requests where the individual states disclosure could endanger them; also covers requests to restrict disclosure to a health plan. ↩
  10. Tanner MR, Miele P, Carter W, et al. Preexposure Prophylaxis for Prevention of HIV Acquisition Among Adolescents: Clinical Considerations, 2020. MMWR Recommendations and Reports. 2020;69(3):1–12. Centers for Disease Control and Prevention. Minor-consent law analysis, the Explanation of Benefits disclosure mechanism, ATN 110/113/117 bone and adherence findings, and the finding that adherence declined when visits moved from monthly to quarterly. ↩
  11. CDC — Clinical Guidance for PrEP. CDC HIV Nexus (updated April 30, 2026). Approved PrEP medications for adults and adolescents weighing at least 77 lb (35 kg), the F/TAF receptive-vaginal-sex exclusion, adolescent confidentiality and consent guidance, bone-density considerations, 2-1-1 dosing cautions, syringe-access guidance, and the PrEPline number; also contains the outdated statement that cabotegravir is not recommended for adolescents under 18. ↩
  12. APRETUDE (cabotegravir extended-release injectable suspension) prescribing information, 2025 (PDF). U.S. Food and Drug Administration. Indicated for PrEP in adults and adolescents weighing at least 35 kg; adolescent indication supported by open-label trials HPTN 083-01 and HPTN 084-01 in 64 adolescents aged 12 to under 18, of whom 62 received at least one injection with safety comparable to adults. ↩
  13. YEZTUGO (lenacapavir) prescribing information, 2025 (PDF). U.S. Food and Drug Administration. Approved June 18, 2025 for PrEP in adults and adolescents weighing at least 35 kg, dosed 927 mg subcutaneously every 26 weeks after initiation dosing; supported by the PURPOSE 1 and PURPOSE 2 trials. ↩
  14. CDC Recommendation for Use of Lenacapavir for HIV Preexposure Prophylaxis — United States, 2025. MMWR. 2025;74(35). Centers for Disease Control and Prevention. Strong recommendation for lenacapavir injections every six months as PrEP for people weighing at least 77 lb (35 kg), with reported efficacy of 100% among females and 96% in a primarily male population over 52 weeks. ↩
  15. Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN). NIH Eunice Kennedy Shriver National Institute of Child Health and Human Development. The only U.S. multicenter research network devoted to adolescents and young adults aged 13–24 living with or at risk for HIV; started in 2001 by the NICHD Maternal and Pediatric Infectious Disease Branch, co-funded by NIDA and NIMH, current cycle launched 2023. ↩
  16. Ryan White HIV/AIDS Program Parts and Initiatives. Health Resources and Services Administration (HRSA). Program structure (Parts A, B, C, D, F), with Part D funding medical care for low-income women, infants, children, and youth with HIV plus support services for family members; more than half of all people diagnosed with HIV in the U.S. — over 600,000 people — receive program services each year. ↩
  17. CDC — Getting Tested for HIV (self-testing, window periods and confirmatory testing); CDC — Clinical Guidance for PrEP (blood testing, regimen-specific monitoring and limitations of oral self-tests). Program evidence: CDC MMWR — Together TakeMeHome, first-year findings (2024); current ordering information: Together TakeMeHome — About. ↩
  18. The Trevor Project — Get Help. The Trevor Project. Crisis counseling for LGBTQ+ young people by text, chat, or phone, 24 hours a day, 365 days a year from anywhere in the U.S.; confidential and 100% free, with stated limits in cases of abuse or imminent suicide. ↩
  19. 988 Suicide & Crisis Lifeline. Substance Abuse and Mental Health Services Administration (SAMHSA). Federal crisis line reachable by call or text to 988. ↩
  20. Policy Tracker: Youth Access to Gender Affirming Care and State Policy Restrictions. KFF (last updated August 14, 2026). 27 states have enacted laws or policies limiting youth access; about half of trans youth aged 13–17 live in such a state; 25 bans remain in place with Montana and Arkansas blocked by court order; 24 states impose professional or legal penalties on practitioners. ↩
  21. New Regulation Prohibits Federal Medicaid Funds From Covering Gender-Affirming Medical Care for Young People. KFF, August 13, 2026. Analysis of the August 11, 2026 CMS final rule: scope (puberty blockers, hormone therapy, surgery for enrollees under 18 in Medicaid and under 19 in CHIP), the up-to-six-month hormone tapering period, the state-only-funds exception, and the estimated 130,000 young trans Medicaid/CHIP enrollees affected. ↩
  22. State of the HIV Epidemic, Florida, 2023 (PDF). Florida Department of Health. Florida's 4,725 new diagnoses in 2023 with age breakdown (139 aged 13–19; 1,285 aged 20–29), 128,497 people with HIV living in Florida at year-end 2023, third-highest state diagnosis rate, county and metropolitan-area rankings, the CDC once-in-a-lifetime testing recommendation for ages 13–64, and the Florida HIV/AIDS Hotline numbers. ↩
  23. Together TakeMeHome — FAQ: national program eligibility and test-specific age limits. Source. Checked September 20, 2026. ↩
  24. NIH — Preventing Perinatal Transmission of HIV During Pregnancy and Childbirth. Source. Checked September 20, 2026. ↩
  25. CMS — August 11, 2026 announcement of Medicaid/CHIP final rule; scheduled effective date October 13, 2026. Source. Checked September 20, 2026. ↩
  26. NCCC — PrEP consultations for clinicians: 844-275-6222, Monday–Friday 7 a.m.–5 p.m. Pacific, excluding holidays. Source. Checked September 21, 2026. ↩
Search RiseUpToHIV